Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis
Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis
This study assessed the efficacy, safety, and tolerability of 2 doses of oral fingolimod
 (1.25 mg/day and 0.5 mg/day) compared to placebo in patients with relapsing-remitting
 multiple sclerosis (RRMS)
Inclusion Criteria:

 -  Male and female patients between ages 18-55 with a diagnosis of multiple sclerosis

 -  Patients with a relapsing-remitting disease course

 -  Patients with EDSS score of 0-5.5

 Exclusion Criteria:

 -  Patients with other chronic disease of the immune system, malignancies, acute
 pulmonary disease, cardiac failure, etc.

 -  Pregnant or nursing women

 Other protocol-defined inclusion/exclusion criteria applied to this study.